Westborough-based information technology firm eClinicalWorks said it's investing another $50 million in its mobile health business unit, allowing the company to hire an additional 100 software developers.
Massachusetts has come to be known as the Hollywood of the East, but it's been lacking one crucial element: a professional film studio where crews can shoot indoor scenes with all the necessary equipment on hand.
That changed this fall when New England Studios finally launched in Devens. A project six years in the making, New England Studios may be the key to acheiving what Massachusetts economic development leaders hoped for when they designed film tax credits to lure the industry here: a new destination for the film industry.
American Superconductor Corp. (AMSC), a Devens-based wind and power grid company, announced it has increased its borrowing capacity through an amendment to its existing loan and a stock sales agreement.
Westborough-based RXi Pharmaceuticals has signed an agreement with a British company to distribute RXi's clinical-stage dermal scarring drug in the European Union ahead of regulatory approval.
RXi said in a statement that Ethicor Ltd., a London-based specialty pharmaceuticals company that distributes unlicensed medicines used for unmet clinical needs, now has the distribution rights to RXI-109 in the European Union with the potential to distribute the drug to other parts of the world before the product is registered in the countries covered by the agreement.
Cardiac and vascular medical device company PLC Systems continued to build on momentum from the first half of the year, increasing revenue 80 percent in the third quarter and narrowing its losses.
Just days before voters in that down go to the polls to determine whether plans for a resort casino in Milford can move forward, state gaming officials have issued a conditional endorsement of the group seeking to build it, ordering it to obtain more money for the project.
RXi Pharmaceuticals of Westborough, which is pursuing approval of a drug aimed at minimizing post-surgical scarring, saw a 61-percent year-over-year increase in revenue for the third quarter, although it posted another loss, the biotech startup reported today.